Valuation: AIT Therapeutics Inc

Market Cap 6.43M 5.62M 5.19M 4.84M 9.13M 608M 9.29M 62.28M 24.18M 300M 24.14M 23.6M 1.04B P/E 2025
-0.4x
P/E 2026 -0.17x
Enterprise Value 18.17M 15.9M 14.68M 13.69M 25.8M 1.72B 26.26M 176M 68.36M 848M 68.26M 66.74M 2.95B EV / Sales 2025
7.78x
EV / Sales 2026 2.48x
Free-Float
96.64%
Yield 2025 *
-
Yield 2026 -
Manager TitleAgeSince
Chief Executive Officer 61 2026-03-26
Director of Finance/CFO 53 2026-01-04
Chief Tech/Sci/R&D Officer - 2024-03-31
Director TitleAgeSince
Director/Board Member 58 2017-08-09
Director/Board Member 54 2018-01-01
Director/Board Member 65 2018-08-12
Change 5-day change 1-year change 3-year change Capi.($)
+3.17%+20.00% - - 6.43M
+2.07%+0.23%-33.28%-16.77% 158B
+1.45%-2.98%-10.26%-11.20% 100B
-0.07%+0.67%-5.63%+47.06% 55.06B
-0.17%-1.69%+55.59%+49.70% 53.4B
+0.55%+5.15%-12.15%-42.68% 41.7B
+0.94%+11.73% - - 33.35B
+2.85%-2.28%-22.84%-47.59% 25.99B
+0.43%+6.72%+64.08%-6.14% 25.36B
+0.82%+3.62%-12.34%-6.41% 20.52B
Average +1.13%+3.07%+2.90%-4.25% 57.06B
Weighted average by Cap. +1.13%+1.38%-6.99%-3.81%

Financials

2025 2026
Net sales 3.7M 3.24M 2.99M 2.79M 5.26M 350M 5.36M 35.91M 13.94M 173M 13.92M 13.61M 602M 7.68M 6.72M 6.2M 5.79M 10.9M 726M 11.1M 74.43M 28.89M 358M 28.85M 28.21M 1.25B
Net income -46.62M -40.81M -37.67M -35.14M -66.21M -4.41B -67.4M -452M -175M -2.18B -175M -171M -7.58B -33.25M -29.1M -26.87M -25.06M -47.22M -3.14B -48.06M -322M -125M -1.55B -125M -122M -5.4B
Net Debt 4.77M 4.18M 3.85M 3.6M 6.78M 451M 6.9M 46.24M 17.95M 223M 17.92M 17.52M 776M 11.74M 10.28M 9.49M 8.85M 16.68M 1.11B 16.97M 114M 44.19M 548M 44.12M 43.13M 1.91B
Logo AIT Therapeutics Inc
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
Employees
-